Apollomics Inc. is a biotechnology company dedicated to the discovery and development of innovative oncology therapies. Their approach focuses on harnessing the immune system and targeting specific molecular pathways to combat cancer, particularly in patients who have exhausted other treatment options. The company emphasizes a science-driven methodology, ensuring that clinical trials are based on sound mechanistic and scientific rationale. This includes rigorous preclinical studies to guide the development of their drug candidates, which are designed to be used as monotherapies or in combination with other treatments to enhance clinical benefits for cancer patients.

The company's R&D pipeline features several promising drug candidates, including Vebreltinib (APL-101) and Uproleselan (APL-106), among others. Apollomics aims to enrich its early-stage pipeline through self-developed technology platforms and has established a global intellectual property portfolio to support its innovative efforts. By leveraging partnerships with other biotechnology firms in both the U.S. and China, Apollomics seeks to unlock synergies that can enhance the development of next-generation therapies, ultimately striving to become a global leader in the oncology field.

United States

Apollomics is an innovative biotechnology company focusing on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer.

Apollomic Inc

Company Details